Lista de obras - Srdan Verstovsek - Dominio Público Uruguay

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies

artículo científico publicado en 2017

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

artículo científico publicado en 2020

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

artículo científico publicado en 2005

3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms

artículo científico publicado en 2017

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

artículo científico publicado en 2004

A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia

artículo científico publicado en 2016

A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis

artículo científico publicado en 2017

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

artículo científico publicado en 2017

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

artículo científico publicado en 2016

A comprehensive review of pacritinib in myelofibrosis

artículo científico

A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia

artículo científico publicado en 2007

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

artículo científico publicado en 2012

A multimodality work-up of patients with Hypereosinophilia

artículo científico publicado en 2018

A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome

artículo científico publicado en 2006

A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia

artículo científico publicado en 2017

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2010

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

artículo científico publicado en 2020

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

artículo científico publicado en 2016

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis

scientific article published on 01 August 2019

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

artículo científico publicado en 2017

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

artículo científico publicado en 2019

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

artículo científico publicado en 2018

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

artículo científico publicado en 2014

A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis

artículo científico publicado en 2017

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

artículo científico publicado en 2013

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

artículo científico publicado en 2008

A phase I clinical trial of darinaparsin in patients with refractory solid tumors.

artículo científico publicado en 2009

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis

artículo científico publicado en 2016

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

artículo científico publicado en 2014

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2014

A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome

scientific article published on 23 May 2013

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

artículo científico publicado en 2008

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

scientific article published on 29 March 2006

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.

artículo científico publicado en 2015

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

artículo científico publicado en 2017

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

artículo científico publicado en 2018

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

artículo científico publicado en 2015

A potential role of ruxolitinib in leukemia

artículo científico publicado en 2011

A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression

artículo científico publicado en 2003

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

artículo científico publicado en 2008

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

scientific article published on 01 September 2020

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

artículo científico publicado en 2005

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

artículo científico publicado en 2005

Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis

scientific article published on 01 February 2010

Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

scientific article published on 01 October 2006

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells

artículo científico publicado en 2006

Activity of alemtuzumab in patients with CD52-positive acute leukemia

scientific article published on 01 June 2006

Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity

artículo científico publicado en 2012

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure

artículo científico publicado en 2017

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

artículo científico publicado en 2013

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2010

Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells

scientific article published on 04 July 2006

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

artículo científico publicado en 2005

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

artículo científico publicado en 2005

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

artículo científico publicado en 2003

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

artículo científico publicado en 2005

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice

artículo científico publicado en 2016

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression

artículo científico publicado en 2013

Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis

artículo científico publicado en 2011

Advances in the management of myelofibrosis

artículo científico publicado en 2012

Advances in the therapy of chronic idiopathic myelofibrosis

artículo científico publicado en 2006

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

artículo científico publicado en 2009

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation

artículo científico publicado en 2010

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis

artículo científico publicado en 2020

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

artículo científico publicado en 2016

An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions

artículo científico publicado en 2006

An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma

artículo científico publicado en 2012

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

artículo científico publicado en 2003

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

artículo científico publicado en 2016

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

artículo científico publicado en 2012

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

artículo científico publicado en 2003

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

artículo científico publicado en 2016

Arsenic derivatives as therapeutic agents for hematologic malignancies

artículo científico publicado en 2004

Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?

artículo científico publicado en 2006

Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition

artículo científico publicado en 2012

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

artículo científico publicado en 2017

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

artículo científico publicado en 2018

Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome

artículo científico publicado en 2015

At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells

artículo científico publicado en 2016

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia

artículo científico publicado en 2020

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2014

Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy

artículo científico publicado en 2011

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

artículo científico publicado en 2016

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study

artículo científico publicado en 2007

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies

artículo científico publicado en 2016

Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.

artículo científico publicado en 2013

Bone marrow findings in blast phase of polycythemia vera

artículo científico publicado en 2017

Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

scientific article published on 23 January 2013

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.

artículo científico publicado en 2017

Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor

artículo científico publicado en 2011

Breakthroughs in myeloproliferative neoplasms

artículo científico

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.

artículo científico publicado en 2018

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein

artículo científico publicado en 2004

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

artículo científico publicado en 2015

Changing myelofibrosis's natural course at last

artículo científico publicado en 2014

Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera

artículo científico publicado en 2017

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

artículo científico publicado en 2010

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

artículo científico publicado en 2017

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

artículo científico publicado en 2014

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

artículo científico publicado en 2019

Chemical and clinical development of darinaparsin, a novel organic arsenic derivative

artículo científico publicado en 2008

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

artículo científico publicado en 2010

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

artículo científico publicado en 2006

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

artículo científico publicado en 2007

Chromosome 5q deletion is extremely rare in patients with myelofibrosis

artículo científico publicado en 2013

Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics

artículo científico publicado en 2015

Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm.

artículo científico publicado en 2015

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

artículo científico publicado en 2009

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

artículo científico publicado en 2016

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

scientific article published on 13 August 2018

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

artículo científico publicado en 2014

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

artículo científico publicado en 2014

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia

scientific article published on 01 July 2003

Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease

scientific article published on 20 March 2006

Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome

artículo científico publicado en 2002

Clinical significance of microcytosis in patients with primary myelofibrosis

artículo científico publicado en 2014

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

artículo científico publicado en 2016

Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.

artículo científico publicado en 2015

Clinical value of event-free survival in acute myeloid leukemia

scientific article published on 01 April 2020

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

artículo científico publicado en 2006

Clofarabine combinations as acute myeloid leukemia salvage therapy

artículo científico publicado en 2008

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

artículo científico publicado en 2017

Comorbidities predict worse prognosis in patients with primary myelofibrosis

artículo científico publicado en 2014

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

scientific article published on 02 August 2013

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

artículo científico publicado en 2011

Competing cell clones in myeloproliferative neoplasm

artículo científico publicado en 2010

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

artículo científico publicado en 2003

Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis

artículo científico publicado en 2016

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

artículo científico publicado en 2017

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

artículo científico publicado en 2016

Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

scientific article published on 21 November 2019

Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.

artículo científico publicado en 2016

Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia

artículo científico publicado en 2007

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

artículo científico publicado en 2015

Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

artículo científico publicado en 2010

Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma

scientific article published on 01 November 1995

Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation

artículo científico publicado en 2009

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

artículo científico publicado en 2008

DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia

artículo científico publicado en 2015

Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase

artículo científico publicado en 2011

Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.

artículo científico publicado en 2003

Developmental Therapeutics in Myeloproliferative Neoplasms

artículo científico publicado en 2017

Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center

artículo científico publicado en 2020

Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers

artículo científico publicado en 2013

Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations

scientific article published on 01 February 2010

Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants

scientific article published on 01 January 1995

Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice.

artículo científico publicado en 1998

Doxorubicin-induced DNA degradation in murine thymocytes.

artículo científico publicado en 1994

Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management

artículo científico publicado en 2016

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells

artículo científico publicado en 2013

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome

artículo científico publicado en 2015

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

artículo científico publicado en 2009

ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant

artículo científico publicado en 2014

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation

artículo científico publicado en 2006

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

artículo científico publicado en 2013

Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.

artículo científico publicado en 2003

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial

artículo científico publicado en 2013

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

artículo científico publicado en 2008

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

artículo científico publicado en 2006

Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

artículo científico publicado en 2014

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

artículo científico publicado en 2019

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2009

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

artículo científico publicado en 2018

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

artículo científico publicado en 2015

Efficacy of ruxolitinib for myelofibrosis

artículo científico publicado en 2014

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.

artículo científico publicado en 2015

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

artículo científico publicado en 2013

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

artículo científico publicado en 2015

Emerging drugs for essential thrombocythemia

scientific article published on 14 May 2019

Emerging drugs for myelofibrosis

artículo científico publicado en 2012

Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms

scientific article published on 20 June 2019

Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.

artículo científico publicado en 2003

Eosinophilia in Hematologic Disorders

artículo científico publicado en 2015

Eradication of minimal residual disease in hairy cell leukemia

artículo científico publicado en 2006

Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial

artículo científico publicado en 2011

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

artículo científico publicado en 2003

Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis

artículo científico publicado en 2010

Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera

scientific article published on 01 September 2007

Experimental therapeutics for patients with myeloproliferative neoplasias

artículo científico publicado en 2010

Experimental therapy in myelofibrosis with myeloid metaplasia

artículo científico publicado en 2006

Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature

artículo científico publicado en 2014

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

artículo científico publicado en 2009

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

artículo científico publicado en 2020

Flow cytometric immunophenotypic analysis of systemic mastocytosis involving bone marrow

artículo científico publicado en 2014

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

artículo científico publicado en 2003

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

artículo científico publicado en 2006

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

artículo científico publicado en 2003

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

artículo científico publicado en 2003

Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3

artículo científico publicado en 2015

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome

artículo científico publicado en 2012

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias

artículo científico publicado en 2010

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.

artículo científico publicado en 2014

Givinostat: an emerging treatment for polycythemia vera

artículo científico publicado en 2020

Granulocytic sarcoma with massive scalp involvement

scientific article published on 01 April 2008

Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance

artículo científico publicado en 2017

Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells

artículo científico publicado en 2011

Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour

scientific article published on 20 June 2006

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

artículo científico publicado en 2012

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

artículo científico publicado en 2003

Highlights in myeloproliferative neoplasms from the 2017 American Society of Hematology Annual Meeting: commentary

artículo científico publicado en 2018

Highlights in polycythemia vera from the 2016 EHA congress.

artículo científico publicado en 2016

Highly reproducible detection and semi-quantification of telomerase activity

scientific article published on 01 May 2001

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

artículo científico publicado en 2017

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms

artículo científico

How we diagnose and treat WHO-defined systemic mastocytosis in adults

artículo científico publicado en 2008

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

artículo científico publicado en 2020

Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease

artículo científico publicado en 2007

Imatinib effect on growth and signal transduction in polycythemia vera

artículo científico publicado en 2007

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status

artículo científico publicado en 2008

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

artículo científico publicado en 2008

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

artículo científico publicado en 2009

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

artículo científico publicado en 2003

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

artículo científico publicado en 2004

Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.

artículo científico publicado en 2013

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin

artículo científico publicado en 2010

Immunotherapy based approaches in myelofibrosis

artículo científico

Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms

artículo científico publicado en 2014

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center

scientific article published on 01 April 2006

In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines

artículo científico publicado en 2003

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

artículo científico publicado en 2002

Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities

artículo científico publicado en 2015

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

artículo científico publicado en 2003

Inhibition of mammary carcinoma cell proliferation in vitro and tumor growth in vivo by bee venom.

artículo científico publicado en 2003

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.

artículo científico publicado en 2015

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986

artículo científico publicado en 2005

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

artículo científico publicado en 2013

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

artículo científico publicado en 2006

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

artículo científico publicado en 2013

Investigational Janus kinase inhibitors in development for myelofibrosis

artículo científico publicado en 2017

Investigational Janus kinase inhibitors.

artículo científico publicado en 2013

Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms

artículo científico publicado en 2016

Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?

scientific article published on 01 March 2007

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives

artículo científico publicado en 2020

JAK2 inhibitors and myeloproliferative neoplasms.

artículo científico publicado en 2008

JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?

artículo científico publicado en 2012

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

artículo científico

JAK2 inhibitors: A reality? A hope?

artículo científico publicado en 2009

JAK2 inhibitors: are they the solution?

artículo científico publicado en 2011

JAK2 inhibitors: what's the true therapeutic potential?

artículo científico publicado en 2010

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

artículo científico publicado en 2005

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms

artículo científico publicado en 2013

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

artículo científico publicado en 2015

JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis

artículo científico publicado en 2017

JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?

artículo científico publicado en 2006

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

scientific article published on 27 February 2019

Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?

artículo científico

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis

artículo científico publicado en 2014

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

artículo científico publicado en 2011

Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms

artículo científico publicado en 2011

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

artículo científico publicado en 2015

Kit Mutations: New Insights and Diagnostic Value

artículo científico publicado en 2018

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

artículo científico publicado en 2009

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

artículo científico publicado en 2006

Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.

artículo científico publicado en 2007

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

artículo científico publicado en 2017

Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis

artículo científico publicado en 2015

Lipopolysaccharide and splenic tumoricidal macrophage activation

scientific article published on 01 December 1994

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

artículo científico publicado en 2018

Long non-coding RNAs in primary myelofibrosis: the dark matter in hematopoietic progenitor cells?

artículo científico publicado en 2015

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

artículo científico publicado en 2018

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

scientific article published on 23 January 2020

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody

artículo científico publicado en 2012

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr

artículo científico publicado en 2015

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

artículo científico publicado en 2016

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

artículo científico publicado en 2012

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2020

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

artículo científico publicado en 2016

Long-term results of frontline dasatinib in chronic myeloid leukemia

scientific article published on 30 January 2020

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

artículo científico publicado en 2004

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

artículo científico publicado en 2017

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

artículo científico publicado en 2017

MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells

artículo científico publicado en 2009

MPN-associated myelofibrosis (MPN-MF).

artículo científico publicado en 2010

MYC protein expression is an important prognostic factor in acute myeloid leukemia

artículo científico publicado en 2018

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

artículo científico publicado en 2011

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

artículo científico publicado en 2004

Management of Myelofibrosis-Related Cytopenias

artículo científico publicado en 2018

Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience

scientific article published on 07 December 2020

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes

artículo científico publicado en 2013

Management of myelofibrosis after ruxolitinib failure

scientific article published on 16 April 2020

Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience

artículo científico publicado en 2004

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

artículo científico publicado en 2017

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

artículo científico publicado en 2017

Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome

artículo científico publicado en 2017

Mechanisms of thrombogenesis in polycythemia vera

artículo científico publicado en 2014

Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors

artículo científico publicado en 2020

Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge

artículo científico publicado en 2013

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation

scientific article published on 11 July 2019

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

artículo científico publicado en 2013

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a

artículo científico publicado en 2013

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance

artículo científico

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

artículo científico publicado en 2005

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

artículo científico publicado en 2017

Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis

artículo científico publicado en 2007

Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.

artículo científico publicado en 2017

Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line

artículo científico publicado en 2002

Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias

artículo científico publicado en 2008

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable

artículo científico publicado en 2018

Mutational profiling in myelofibrosis: implications for management

scientific article published on 19 October 2019

Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.

artículo científico publicado en 2006

Mycotic pulmonary artery aneurysm due to Aspergillus infection in a patient with leukemia: case report and review of the literature

artículo científico publicado en 2010

Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.

artículo científico publicado en 2014

Myelofibrosis osteoclasts are clonal and functionally impaired

scientific article published on 11 February 2019

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

artículo científico publicado en 2014

Myelofibrosis: an update on drug therapy in 2016.

artículo científico publicado en 2016

Myeloid/lymphoid neoplasms with FGFR1 rearrangement

artículo científico publicado en 2017

Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.

artículo científico publicado en 2016

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2016

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

artículo científico publicado en 2003

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

artículo científico publicado en 2017

Neutrophilic-chronic myeloid leukemia

Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course

artículo científico publicado en 2002

New Concepts of Treatment for Patients with Myelofibrosis

scientific article published on 24 January 2019

New JAK2 inhibitors for myeloproliferative neoplasms

artículo científico publicado en 2011

New Therapeutic Approaches in Polycythemia Vera

artículo científico publicado en 2015

New Therapies in Development for Myelofibrosis

scientific article published on 01 September 2020

New approaches in the treatment of myelofibrosis

artículo científico publicado en 2005

New therapies for polycythemia vera.

artículo científico publicado en 2015

Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner

artículo científico publicado en 2014

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells

artículo científico publicado en 2017

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms

artículo científico publicado en 2020

Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors

artículo científico publicado en 2019

Novel and emerging therapies for the treatment of polycythemia vera

artículo científico publicado en 2014

Novel approaches in the treatment of systemic mastocytosis

artículo científico publicado en 2006

Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions

artículo científico publicado en 2017

Novel therapies for myelofibrosis

artículo científico publicado en 2015

Novel treatment strategies for myeloproliferative neoplasms

artículo científico publicado en 2019

Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera

artículo científico publicado en 2006

Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies

artículo científico publicado en 2004

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

artículo científico publicado en 2006

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

artículo científico publicado en 2013

Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors

artículo científico publicado en 2020

Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure

scientific article published on 01 April 2007

Outcome of patients with acute myelogenous leukemia after second salvage therapy

artículo científico publicado en 2005

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

artículo científico publicado en 2011

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

artículo científico publicado en 2004

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

artículo científico publicado en 2015

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

artículo científico publicado en 2017

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

artículo científico publicado en 2019

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

artículo científico publicado en 2016

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study

artículo científico publicado en 2007

Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden

artículo científico publicado en 2020

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.

artículo científico publicado en 2018

Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis

artículo científico publicado en 2014

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

artículo científico publicado en 2016

Patient Perceptions in Mast Cell Disorders

artículo científico publicado en 2018

Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms

artículo científico publicado en 2017

Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome

artículo científico publicado en 2013

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis

artículo científico publicado en 2017

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial

artículo científico publicado en 2017

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

artículo científico publicado en 2009

Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders

artículo científico publicado en 2006

Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis

artículo científico publicado en 2018

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

artículo científico publicado en 2019

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

artículo científico publicado en 2005

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

scientific article published on 01 September 2007

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

artículo científico publicado en 2016

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

artículo científico publicado en 2006

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

artículo científico publicado en 2003

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

artículo científico publicado en 2009

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

artículo científico publicado en 2016

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

artículo científico publicado en 2012

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

artículo científico publicado en 2003

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

artículo científico publicado en 2004

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies

artículo científico publicado en 2013

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

artículo científico publicado en 2013

Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies

artículo científico publicado en 2015

Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome

artículo científico publicado en 2008

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

artículo científico publicado en 2005

Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation

scientific article published on 14 September 2018

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

artículo científico publicado en 2010

Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia

artículo científico publicado en 2020

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

artículo científico publicado en 2007

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

artículo científico publicado en 2006

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

artículo científico publicado en 2015

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

artículo científico publicado en 2009

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

artículo científico publicado en 2008

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

artículo científico publicado en 2009

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

artículo científico publicado en 2007

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

artículo científico publicado en 2005

Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis

artículo científico publicado en 2010

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

artículo científico publicado en 2014

Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

artículo científico publicado en 2010

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

artículo científico publicado en 2003

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

artículo científico publicado en 2020

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

artículo científico publicado en 2018

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

artículo científico publicado en 2011

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

artículo científico publicado en 2002

Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome

scientific article published on 01 August 2001

Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes

artículo científico publicado en 2002

Polycythemia vera is not initiated by JAK2V617F mutation.

artículo científico publicado en 2007

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

artículo científico publicado en 2009

Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis

artículo científico publicado en 2022

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.

artículo científico publicado en 2017

Practical management of patients with myelofibrosis receiving ruxolitinib

artículo científico publicado en 2013

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms

artículo científico publicado en 2018

Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders

artículo científico publicado en 2008

Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor

artículo científico publicado en 2010

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

artículo científico publicado en 2010

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

artículo científico publicado en 2003

Preface

scientific article published on 01 June 2014

Pregnancy in a patient with hypereosinophilic syndrome

artículo científico publicado en 2008

Prevalence of pulmonary hypertension in myelofibrosis

artículo científico publicado en 2020

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

artículo científico publicado en 2016

Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS.

artículo científico publicado en 2013

Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia

artículo científico publicado en 2009

Primary autoimmune myelofibrosis: a case report and review of the literature

artículo científico publicado en 2016

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

artículo científico publicado en 2007

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib

artículo científico publicado en 2015

Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes

artículo científico publicado en 2019

Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient

artículo científico publicado en 2009

Prognosis of Primary Myelofibrosis in the Genomic Era

artículo científico publicado en 2016

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

artículo científico publicado en 2017

Prognostic impact of RAS-pathway mutations in patients with myelofibrosis

artículo científico publicado en 2019

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

artículo científico publicado en 2011

Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis

artículo científico publicado en 2013

Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis

artículo científico publicado en 2007

Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia

artículo científico publicado en 2013

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

artículo científico publicado en 2008

Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia

scientific article published on 01 March 2002

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

artículo científico publicado en 2017

Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia

scientific article published on 01 March 2002

Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era

artículo científico publicado en 2020

Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?

artículo científico publicado en 2017

Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study

artículo científico publicado en 2013

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

artículo científico publicado en 2007

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

scientific article published on 30 August 2007

Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

artículo científico publicado en 2009

Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice.

artículo científico publicado en 2000

Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis

artículo científico publicado en 2017

Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease

scientific article published on 05 April 2007

RBC-transfusion guidelines update

artículo científico publicado en 2012

Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States

scientific article published on 07 May 2020

Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal

artículo científico publicado en 2014

Renal complications of primary myelofibrosis

artículo científico publicado en 2018

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

artículo científico publicado en 2003

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

artículo científico publicado en 2004

Retrospect of hematologic malignancies 2010

scientific article published on 23 May 2011

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

artículo científico publicado en 2013

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

artículo científico publicado en 2013

Role of angiogenesis in chronic lymphocytic leukemia

artículo científico publicado en 2006

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis

artículo científico publicado en 2016

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera

artículo científico publicado en 2024

Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis

artículo científico publicado en 2014

Ruxolitinib and survival improvement in patients with myelofibrosis.

artículo científico publicado en 2014

Ruxolitinib dose management as a key to long-term treatment success

artículo científico publicado en 2016

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

artículo científico publicado en 2017

Ruxolitinib for essential thrombocythemia?

artículo científico publicado en 2017

Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival

artículo científico publicado en 2013

Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial

artículo científico publicado en 2017

Ruxolitinib for the treatment of myelofibrosis.

artículo científico publicado en 2011

Ruxolitinib for the treatment of myelofibrosis: its clinical potential

artículo científico publicado en 2012

Ruxolitinib for the treatment of patients with polycythemia vera.

artículo científico

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

scientific article published on 18 June 2015

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.

artículo científico publicado en 2017

Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis

scientific article published on 15 May 2019

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

artículo científico

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

artículo científico publicado en 2015

Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis

artículo científico publicado en 2011

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

artículo científico publicado en 2016

Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis

artículo científico publicado en 2013

Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms

artículo científico publicado en 2014

Ruxolitinib: the first agent approved for myelofibrosis

artículo científico publicado en 2012

SMAC mimetics as potential cancer therapeutics in myeloid malignancies

scientific article published on 05 March 2019

SOHO State of the Art Updates and Next Questions: Myelofibrosis

artículo científico publicado en 2019

SOHO State-of-the-Art Update and Next Questions: MPN.

artículo científico publicado en 2018

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

artículo científico publicado en 2003

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

artículo científico publicado en 2010

Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?

artículo científico publicado en 2016

Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience

artículo científico publicado en 2015

Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation

artículo científico publicado en 2017

Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406

artículo científico publicado en 2007

Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome

scientific article published on 01 August 2001

Significance of cytogenetic abnormalities in patients with polycythemia vera

artículo científico publicado en 2013

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

artículo científico publicado en 2013

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

artículo científico publicado en 2017

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

artículo científico publicado en 2013

Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial

artículo científico publicado en 2013

Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2.

artículo científico publicado en 1996

Spinal epidural granulocytic sarcoma in non-leukemic patient

scientific article published on 26 December 2008

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.

artículo científico publicado en 2011

Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation

artículo científico publicado en 2013

Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

artículo científico

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

artículo científico publicado en 2006

Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells

artículo científico publicado en 2014

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate

artículo científico publicado en 2005

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

artículo científico publicado en 2009

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

artículo científico publicado en 2004

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

artículo científico publicado en 2005

Survival following allogeneic transplant in patients with myelofibrosis

artículo científico publicado en 2020

Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis

scholarly article by Srdan Verstovsek et al published October 2018 in Hematological Oncology

Synchronous primary cancers of the breast and cervix: planning multidisciplinary primary treatment [clinico-pathological conference]

scientific article published on 01 February 2000

Systematic Use of Fluorescence in situ Hybridization (FISH) and Clinicopathological Features in the Screening of PDGFRB Rearrangements of Patients with Myeloid/Lymphoid Neoplasms

artículo científico publicado en 2020

Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis

scientific article published on 2 Dec 2016

Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components

artículo científico publicado en 2013

T-cell prolymphocytic leukemia: a single-institution experience

scientific article published on 01 November 2005

TP53 mutation is rare in primary myelofibrosis

artículo científico publicado en 2012

Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.

artículo científico publicado en 2016

Targeting cistrome and dysregulated transcriptome of post-MPN sAML.

artículo científico publicado en 2017

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

artículo científico publicado en 2018

Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia

artículo científico publicado en 2004

Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia

artículo científico publicado en 2003

Thalidomide therapy for myelofibrosis with myeloid metaplasia

scientific article published on 01 May 2006

The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells

artículo científico publicado en 2010

The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia

scientific article published on 17 June 2020

The Evolving Landscape of JAK Inhibition in the Treatment of Myelofibrosis ⬇️

artículo científico publicado en 2020

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

artículo científico publicado en 2008

The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication

artículo científico publicado en 2020

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

artículo científico publicado en 2009

The Rationale for Immunotherapy in Myeloproliferative Neoplasms

scientific article published on 01 August 2019

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

artículo científico publicado en 2005

The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

artículo científico publicado en 2007

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis

artículo científico publicado en 2013

The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes

artículo científico publicado en 2013

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

artículo científico publicado en 2011

The co-occurrence of driver mutations in chronic myeloproliferative neoplasms

artículo científico publicado en 2018

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival

scientific article published on 19 November 2019

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

artículo científico publicado en 2020

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

artículo científico publicado en 2015

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).

artículo científico publicado en 2016

The evolution and clinical relevance of prognostic classification systems in myelofibrosis

artículo científico

The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy

artículo científico publicado en 2015

The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis

scientific article published on 01 May 2019

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

artículo científico publicado en 2007

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

artículo científico publicado en 2016

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms

artículo científico publicado en 2008

The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells

artículo científico publicado en 2012

The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate

artículo científico publicado en 2003

The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia

artículo científico publicado en 2012

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

artículo científico publicado en 2009

The role of macrophages in antitumor defense of patients with ovarian cancer.

artículo científico publicado en 1999

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.

artículo científico publicado en 2017

The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

artículo científico publicado en 2017

Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere

artículo científico publicado en 2018

Therapeutic advances in myeloproliferative neoplasms: the role of new-small molecule inhibitors.

artículo científico publicado en 2012

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

artículo científico publicado en 2015

Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly

artículo científico publicado en 2012

Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea

artículo científico

Therapeutic potential of JAK2 inhibitors

artículo científico publicado en 2009

Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis

scientific article published on 09 March 2010

Therapy with JAK2 inhibitors for myeloproliferative neoplasms

artículo científico publicado en 2012

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

artículo científico publicado en 2012

Therapy-related myelofibrosis does not appear to exist

scientific article published on 26 May 2017

Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis

scientific article published on 17 September 2007

Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation.

artículo científico publicado en 1998

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

scientific article published on 14 July 2020

Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis

artículo científico publicado en 2013

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

artículo científico publicado en 2017

Treating Leukemia in the Time of COVID-19

scientific article published on 11 May 2020

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

artículo científico publicado en 2003

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

artículo científico publicado en 2003

Treatment of aggressive systemic mastocytosis with daclizumab

artículo científico publicado en 2010

Treatment of myelofibrosis in younger patients: to transplant or not?

artículo científico publicado en 2009

Treatment of systemic mastocytosis with denileukin diftitox

scientific article published on 01 December 2007

Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor

scientific article published on 01 August 2018

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome

artículo científico publicado en 2006

Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation

artículo científico publicado en 2004

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

artículo científico publicado en 2013

Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript

scientific article published on 21 November 2018

Updates in the management of polycythemia vera and essential thrombocythemia

artículo científico publicado en 2019

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

artículo científico publicado en 2005

Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

scientific article published on 31 December 2020

Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia

artículo científico publicado en 2014

Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis

scientific article published on 15 November 2018

Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow

scientific article published on 19 September 2008

Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples

artículo científico publicado en 2013

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse

scientific article published on 01 July 2006

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation

artículo científico publicado en 2008

What are RBC-transfusion-dependence and -independence?

scientific article published on 07 August 2010

What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?

artículo científico publicado en 2013

miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2

scientific article published on 16 January 2020

Lista de obras de Srdan Verstovsek

'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia

A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

A comprehensive review of pacritinib in myelofibrosis

A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

A multimodality work-up of patients with Hypereosinophilia

A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome

A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

A phase I clinical trial of darinaparsin in patients with refractory solid tumors.

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

A potential role of ruxolitinib in leukemia

A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis

Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells

Activity of alemtuzumab in patients with CD52-positive acute leukemia

Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity

Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome

Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression

Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis

Advances in the management of myelofibrosis

Advances in the therapy of chronic idiopathic myelofibrosis

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions

An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

Arsenic derivatives as therapeutic agents for hematologic malignancies

Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?

Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome